{"id":"NCT01900704","sponsor":"Serenity Pharmaceuticals, Inc.","briefTitle":"Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4","officialTitle":"A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2013-07-16","resultsPosted":"2020-11-09","lastUpdate":"2020-11-09"},"enrollment":810,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Nocturia"],"interventions":[{"type":"DRUG","name":"SER120 750 ng","otherNames":[]},{"type":"DRUG","name":"SER120 1500 ng","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"SER120 750 ng","type":"EXPERIMENTAL"},{"label":"SER120 1500 ng","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia","primaryOutcome":{"measure":"Number of Nocturic Episodes at the End of Treatment Compare to Prior to Treatment","timeFrame":"12 weeks","effectByArm":[{"arm":"SER120 750 ng","deltaMin":-1.4,"sd":0.06},{"arm":"SER120 1500 ng","deltaMin":-1.5,"sd":0.06},{"arm":"Placebo","deltaMin":-1.2,"sd":0.06}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":266},"commonTop":["Nasal discomfort","Headache","Urinary tract infection"]}}